ResMed (RMD) is back on investors’ radar after its Q3 FY2026 results highlighted revenue growth, wider margins, solid operating cash flow and capital returns to shareholders, prompting fresh questions about what is already priced into the stock.

At a share price of $194.32, ResMed has seen a 1 day share price return of 4.22%, while its 90 day share price return is down 23.15% and the 1 year total shareholder return is down 21.41%. This suggests recent momentum is still weak despite interest around Q3 FY2026 results and the Noctrix Health acquisition.

If ResMed’s recent moves in sleep and respiratory care have your attention, it can be worth scanning other healthcare technology opportunities via our screener of 40 healthcare AI stocks

With the stock down over the past year but trading below some intrinsic value estimates, the key question now is simple: are you looking at a genuine mispricing, or is the market already baking in years of future growth?

Most Popular Narrative: 6.5% Overvalued

At $194.32, ResMed trades modestly above the most followed fair value estimate of $182.45, which is based on a discounted cash flow narrative using a 7.8% discount rate.

GLP-1 therapies are being framed internally as a once-in-a-generation demand opportunity. However, if broader weight loss adoption or new clinical data leads to fewer patients requiring CPAP, growth in device and mask revenue could fall short of current expectations and pressure earnings.

Want to see what that tension means for the numbers? The narrative leans on moderate revenue growth, firmer margins and a lower future earnings multiple to anchor its valuation.

Result: Fair Value of $182.45 (OVERVALUED)

However, there are still clear risks, including GLP 1 therapies reducing CPAP demand, as well as integration or reimbursement setbacks from deals like VirtuOx and Noctrix.

Wall Street's queuing for one rocket. While SpaceX counts down to its IPO, other companies tied to the new space race are already in orbit. → 20 Compelling Space Companies watchlist · Global Space Race Investing Ideas screener · Scan the sector by valuation on Rocket Lab's valuation page.

Another View: Earnings Multiple Signals Room To Move

While the bearish narrative sees ResMed as 6.5% overvalued at $194.32, the current P/E of 18.5x tells a different story. It sits well below the peer average of 24.2x and the fair ratio of 23.3x, which points to a gap the market could still close in either direction.

For investors who prefer simple comparisons, this kind of discount can hint at valuation risk if sentiment turns, or potential upside if expectations reset more positively. The key question is which way that gap is more likely to resolve.

Next Steps

With sentiment clearly mixed, this is the moment to move fast, review the underlying data for yourself and pressure test the bullish points that others are watching. To see why some investors are optimistic, take a closer look at the 4 key rewards

Looking for more investment ideas?

If you are serious about building a stronger portfolio, do not stop with just one stock. Use the tools available and keep widening your opportunity set.

• Spot potential bargains that combine quality with attractive pricing by scanning our list of 47 high quality undervalued stocks.
• Strengthen your income stream by focusing on companies in the 10 dividend fortresses that aim to support higher yields.
• Reduce portfolio stress by concentrating on companies in the 64 resilient stocks with low risk scores that score well on resilience.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.